<DOC>
	<DOC>NCT02421627</DOC>
	<brief_summary>To observe the safety and efficacy of moxibustion on diarrhea-predominant irritable bowel syndrome and evaluation by Magnetic Resonance Imaging (MRI).</brief_summary>
	<brief_title>Moxibustion for Diarrhea-predominant Irritable Bowel Syndrome</brief_title>
	<detailed_description>1. A randomized controlled trial 2. Moxibustion treatment, placebo control 3. To observe the safety and efficacy of moxibustion treatment versus placebo control 4. Evaluation by structural MRI and resting state-functional MRI</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>1. Diarrheapredominant IBS patients who met the Rome III diagnostic criteria; 2. Age 1865 years old, male or female; 3. Volunteered for the trial, signed the informed consent 1. Intestinal organic disease; 2. Constipationpredominant IBS; 3. Alternating diarrhea and constipation IBS; 4. Unstructured IBS; 5. At the same time, application of smecta, dicetel, cisapride or traditional Chinese medicine; 6. Combined liver, kidney, heart or mental disease patients; 7. Under the age of 18 or above the age of 65 patients; 8. Pregnant or lactating women.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>moxibustion</keyword>
	<keyword>irritable bowel syndrome</keyword>
	<keyword>Magnetic Resonance Imaging</keyword>
</DOC>